STOCKWATCH
·
Biotechnology: Pharmaceutical Preparations
Quarterly ResultMay 14, 2026, 04:13 PM

BullFrog AI Q1 Net Loss Narrows to $1.59M; Regains Nasdaq Compliance

AI Summary

BullFrog AI Holdings reported a narrowed net loss of $1.59 million for the first quarter of 2026, an improvement from $2.02 million in the prior year. The company significantly increased its cash and cash equivalents to $5.08 million and total stockholders' equity to $4.89 million, primarily driven by $4.59 million in net cash from financing activities. This capital raise enabled the company to regain compliance with Nasdaq's Stockholders' Equity Rule on April 21, 2026, though it remains subject to a one-year monitoring period. However, BullFrog AI also received a Nasdaq notice in February 2026 regarding non-compliance with the minimum $1.00 bid price requirement, for which it has until August 10, 2026, to regain compliance.

Key Highlights

  • Net loss for Q1 2026 narrowed to $1,593,161 from $2,017,553 in Q1 2025.
  • Cash and cash equivalents increased to $5,080,463 as of March 31, 2026.
  • Total stockholders' equity rose to $4,886,791 as of March 31, 2026.
  • Net cash provided by financing activities was $4,590,846 in Q1 2026.
  • Company regained compliance with Nasdaq's $2.5M Stockholders' Equity Rule on April 21, 2026.
  • Received Nasdaq notice on Feb 10, 2026, for not meeting the $1.00 minimum bid price.
  • Operating expenses decreased to $1,614,627 in Q1 2026 from $2,056,620 in Q1 2025.
  • No collaboration revenue was recognized in Q1 2026 or Q1 2025.
BFRG
Biotechnology: Pharmaceutical Preparations
BullFrog AI Holdings, Inc.

Price Impact